TABLE 2.

Key amendments to FIGO 2018 staging

Allowing use of any imaging and/or pathologic findings for allocating stage (previously only clinical exam)
Stage I  Amendments to microscopic pathologic findings and size designation  Allowing use of imaging and/or pathologic assessment of tumor size
Stage II  Allowing use of imaging and/or pathologic assessment of size and extent
Stage III  Including nodal involvement as part of staging  Allowing assessment of retroperitoneal lymph nodes by imaging and/or pathologic findings and if deemed metastatic the case is designated as IIIC1 (pelvic/parametrial LN+) or IIIC2 (para-aortic LN+) with notation of method used for stage allocation
No recommendations for routine investigations, which are to be decided on the basis of clinical findings and standard of care. The revised staging system does not mandate the use of a specific imaging technique, lymph node biopsy or surgical assessment of tumor. In low-resourced conditions, clinicians can continue to assess clinically as before.
The method by which tumor is measured should be recorded (r/radiology, p/pathology)